Ehsan Moazen-Zadeh and Igor I. Galynker* Pages 733 - 735 ( 3 )
Cannabidiol (CBD) is gaining considerable attention in the research community with promising results in a variety of neuropsychiatric conditions. In particular, there are replicated findings for the therapeutic effects of CBD on psychotic and anxiety symptoms as well as substance use disorders, all of which are highly prevalent in patients who present with suicidality. Meanwhile, there has been a lack of suicide research on cannabidiol. This perspective provides an overview of the available evidence, potential reasons behind the halt in suicide research on cannabidiol, and recommendations for future investigations.
Cannabidiol, cannabis, marijuana, suicide, adverse events, psychopharmacology.
Addiction Institute of Mount Sinai, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York